Phase I/II Study Combining Tosedostat With Capecitabine in Patients With Metastatic Pancreatic Adenocarcinoma
Phase of Trial: Phase I/II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Capecitabine (Primary) ; Tosedostat (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 26 Jan 2017 Planned End Date changed from 1 Apr 2018 to 31 Mar 2019.
- 26 Jan 2017 Planned primary completion date changed from 1 Jul 2017 to 31 Dec 2017.